Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 20 de 43
Filtrar
Más filtros










Base de datos
Intervalo de año de publicación
1.
Antiviral Res ; 217: 105699, 2023 09.
Artículo en Inglés | MEDLINE | ID: mdl-37549849

RESUMEN

Epstein-Barr virus (EBV) is a highly prevalent human herpesvirus that persists for life in more than 95% of the adult population. EBV usually establishes an asymptomatic life-long infection, but it is also associated with malignancies affecting B lymphocytes and epithelial cells mainly. The virus alternates between a latent phase and a lytic phase, both of which contribute to the initiation of the tumor process. So far, there is only a limited number of antiviral molecules against the lytic phase, most of them targeting viral replication. Recent studies provided evidence that EBV uses components of the NLRP3 inflammasome to enter the productive phase of its cycle following activation in response to various stimuli. In the present work, we demonstrate that shikonin, a natural molecule with low toxicity which is known to inhibit inflammasome, can efficiently repress EBV reactivation. Similar results were obtained with apigenin and OLT 1177, two other NLRP3 inflammasome inhibitors. It is shown herein that shikonin repressed the transcription of reactivation-induced NLRP3 thereby inhibiting inflammasome activation and EBV lytic phase induction.


Asunto(s)
Antiinflamatorios no Esteroideos , Herpesvirus Humano 4 , Inflamasomas , Naftoquinonas , Activación Viral , Inflamasomas/antagonistas & inhibidores , Activación Viral/efectos de los fármacos , Herpesvirus Humano 4/efectos de los fármacos , Naftoquinonas/farmacología , Apigenina/farmacología , Antiinflamatorios no Esteroideos/farmacología , Humanos , Línea Celular , Proteína con Dominio Pirina 3 de la Familia NLR/antagonistas & inhibidores , Línea Celular Tumoral
2.
Oncotarget ; 14: 637-649, 2023 06 21.
Artículo en Inglés | MEDLINE | ID: mdl-37343056

RESUMEN

Diphenyl ditelluride (DPDT) is an organotellurium (OT) compound with pharmacological properties, including antioxidant, antigenotoxic and antimutagenic activities when applied at low concentrations. However, DPDT as well as other OT compounds also show cytotoxicity against mammalian cells when treatments occur at higher drug concentrations. Considering that the underlying mechanisms of toxicity of DPDT against tumor cells have been poorly explored, the objective of our study was to investigate the effects of DPDT against both human cancer and non-tumorigenic cells. As a model, we used the colonic HCT116 cancer cells and the MRC5 fibroblasts. Our results showed that DPDT preferentially targets HCT116 cancer cells when compared to MRC5 cells with IC50 values of 2.4 and 10.1 µM, respectively. This effect was accompanied by the induction of apoptosis and a pronounced G2/M cell cycle arrest in HCT116 cells. Furthermore, DPDT induces DNA strand breaks at concentrations below 5 µM in HCT116 cells and promotes the occurrence of DNA double strand breaks mostly during S-phase as measured by γ-H2AX/EdU double staining. Finally, DPDT forms covalent complexes with DNA topoisomerase I, as observed by the TARDIS assay, with a more prominent effect observed in HCT116 than in MRC5 cells. Taken together, our results show that DPDT preferentially targets HCT116 colon cancer cells likely through DNA topoisomerase I poisoning. This makes DPDT an interesting molecule for further development as an anti-proliferative compound in the context of cancer.


Asunto(s)
Neoplasias del Colon , ADN-Topoisomerasas de Tipo I , Animales , Humanos , Células HCT116 , ADN-Topoisomerasas de Tipo I/metabolismo , Apoptosis , Neoplasias del Colon/tratamiento farmacológico , Neoplasias del Colon/metabolismo , ADN , Mamíferos/metabolismo
3.
Int J Mol Sci ; 23(14)2022 Jul 17.
Artículo en Inglés | MEDLINE | ID: mdl-35887213

RESUMEN

Energy metabolism reprogramming was recently listed as a hallmark of cancer. In this process, the switch from pyruvate kinase isoenzyme type M1 to pyruvate kinase isoenzyme type M2 (PKM2) is believed to play a crucial role. Interestingly, the activity of the active form of PKM2 can efficiently be inhibited by the high-mobility group box 1 (HMGB1) protein, leading to a rapid blockage of glucose-dependent aerobic respiration and cancer cell death. HMGB1 is a member of the HMG protein family. It contains two DNA-binding HMG-box domains and an acidic C-terminal tail capable of positively or negatively modulating its biological properties. In this work, we report that the deletion of the C-terminal tail of HMGB1 increases its activity towards a large panel of cancer cells without affecting the viability of normal immortalized fibroblasts. Moreover, in silico analysis suggests that the truncated form of HMGB1 retains the capacity of the full-length protein to interact with PKM2. However, based on the capacity of the cells to circumvent oxidative phosphorylation inhibition, we were able to identify either a cytotoxic or cytostatic effect of the proteins. Together, our study provides new insights in the characterization of the anticancer activity of HMGB1.


Asunto(s)
Proteína HMGB1 , Dominios HMG-Box , Proteína HMGB1/metabolismo , Isoenzimas/metabolismo , Estructura Terciaria de Proteína , Piruvato Quinasa/metabolismo
4.
Nat Prod Res ; 36(5): 1273-1281, 2022 Mar.
Artículo en Inglés | MEDLINE | ID: mdl-33605174

RESUMEN

Microbial natural products are continuing to be a promising platform for future drug lead discover. As a part of our ongoing research program on fungal natural product, herein we report metabolites isolated from the fungus Parastagonospora nodorum SN15 a pathogen of wheat and related cereals. Its chemical investigation led to the purification of new isoleucinic acid derivatives (1-2) along with the cis procuramine (4). Their structures were determined based on extensive NMR and the relative configuration by comparison of experimental and predicted NMR chemical shifts. All compounds were evaluated for their cytotoxic activity against a panel of human cell lines and some displayed specific feature towards cancer cells compared to normal immortalised fibroblasts.[Formula: see text].


Asunto(s)
Ascomicetos , Triticum , Ascomicetos/metabolismo , Enfermedades de las Plantas/microbiología
5.
Int J Mol Sci ; 22(21)2021 Oct 25.
Artículo en Inglés | MEDLINE | ID: mdl-34768902

RESUMEN

The purine nucleotide adenosine triphosphate (ATP) is known for its fundamental role in cellular bioenergetics. However, in the last decades, different works have described emerging functions for ATP, such as that of a danger signaling molecule acting in the extracellular space on both tumor and stromal compartments. Beside its role in immune cell signaling, several studies have shown that high concentrations of extracellular ATP can directly or indirectly act on cancer cells. Accordingly, it has been reported that purinergic receptors are widely expressed in tumor cells. However, their expression pattern is often associated with contradictory cellular outcomes. In this work, we first investigated gene expression profiles through "RNA-Sequencing" (RNA Seq) technology in four colorectal cancer (CRC) cell lines (HT29, LS513, LS174T, HCT116). Our results demonstrate that CRC cells mostly express the A2B, P2X4, P2Y1, P2Y2 and P2Y11 purinergic receptors. Among these, the P2Y1 and P2Y2 coding genes are markedly overexpressed in all CRC cells compared to the HCEC-1CT normal-like colonic cells. We then explored the cellular outcomes induced by extracellular ATP and adenosine. Our results show that in terms of cell death induction extracellular ATP is consistently more active than adenosine against CRC, while neither compound affected normal-like colonic cell survival. Intriguingly, while for the P2Y2 receptor pharmacological inhibition completely abolished the rise in cytoplasmic Ca2+ observed after ATP exposure in all CRC cell lines, Ca2+ mobilization only impacted the cellular outcome for HT29. In contrast, non-selective phosphodiesterase inhibition completely abolished the effects of extracellular ATP on CRC cells, suggesting that cAMP and/or cGMP levels might determine cellular outcome. Altogether, our study provides novel insights into the characterization of purinergic signaling in CRC.


Asunto(s)
Adenosina Trifosfato/farmacología , Adenosina/farmacología , Biomarcadores de Tumor/metabolismo , Neoplasias Colorrectales/patología , Regulación Neoplásica de la Expresión Génica/efectos de los fármacos , Receptores Purinérgicos/metabolismo , Transcriptoma/efectos de los fármacos , Apoptosis , Biomarcadores de Tumor/genética , Calcio/metabolismo , Señalización del Calcio , Ciclo Celular , Proliferación Celular , Neoplasias Colorrectales/tratamiento farmacológico , Neoplasias Colorrectales/genética , Neoplasias Colorrectales/metabolismo , Espacio Extracelular/metabolismo , Humanos , Receptores Purinérgicos/genética , Células Tumorales Cultivadas
6.
Antioxidants (Basel) ; 10(5)2021 May 04.
Artículo en Inglés | MEDLINE | ID: mdl-34064498

RESUMEN

Specific inhibition of NADPH oxidases (NOX) and NO-synthases (NOS), two enzymes associated with redox stress in tumor cells, has aroused great pharmacological interest. Here, we show how these enzymes distinguish between isomeric 2'- and 3'-phosphate derivatives, a difference used to improve the specificity of inhibition by isolated 2'- and 3'-phosphate isomers of our NADPH analogue NS1. Both isomers become fluorescent upon binding to their target proteins as observed by in vitro assay and in vivo imaging. The 2'-phosphate isomer of NS1 exerted more pronounced effects on NOS and NOX-dependent physiological responses than the 3'-phosphate isomer did. Docking and molecular dynamics simulations explain this specificity at the level of the NADPH site of NOX and NOS, where conserved arginine residues distinguished between the 2'-phosphate over the 3'-phosphate group, in favor of the 2'-phosphate.

7.
Cancers (Basel) ; 13(7)2021 Apr 04.
Artículo en Inglés | MEDLINE | ID: mdl-33916641

RESUMEN

Immunotherapy is a very promising field of research and application for treating cancers, in particular for those that are resistant to chemotherapeutics. Immunotherapy aims at enhancing immune cell activation to increase tumor cells recognition and killing. However, some specific cancer types, such as colorectal cancer (CRC), are less responsive than others to the current immunotherapies. Intrinsic resistance can be mediated by the development of an immuno-suppressive environment in CRC. The mutational status of cancer cells also plays a role in this process. CRC can indeed be distinguished in two main subtypes. Microsatellite instable (MSI) tumors show a hyper-mutable phenotype caused by the deficiency of the DNA mismatch repair machinery (MMR) while microsatellite stable (MSS) tumors show a comparatively more "stable" mutational phenotype. Several studies demonstrated that MSI CRC generally display good prognoses for patients and immunotherapy is considered as a therapeutic option for this type of tumors. On the contrary, MSS metastatic CRC usually presents a worse prognosis and is not responsive to immunotherapy. According to this, developing new and innovative models for studying CRC response towards immune targeted therapies has become essential in the last years. Herein, we review the in vitro and in vivo models used for research in the field of immunotherapy applied to colorectal cancer.

8.
Mar Drugs ; 18(4)2020 Apr 03.
Artículo en Inglés | MEDLINE | ID: mdl-32260204

RESUMEN

High-throughput screening assays have been designed to identify compounds capable of inhibiting phenotypes involved in cancer aggressiveness. However, most studies used commercially available chemical libraries. This prompted us to explore natural products isolated from marine-derived fungi as a new source of molecules. In this study, we established a chemical library from 99 strains corresponding to 45 molecular operational taxonomic units and evaluated their anticancer activity against the MCF7 epithelial cancer cell line and its invasive stem cell-like MCF7-Sh-WISP2 counterpart. We identified the marine fungal Paradendryphiella salina PC 362H strain, isolated from the brown alga Pelvetia caniculata (PC), as one of the most promising fungi which produce active compounds. Further chemical and biological characterizations of the culture of the Paradendryphiella salina PC 362H strain identified (-)-hyalodendrin as the active secondary metabolite responsible for the cytotoxic activity of the crude extract. The antitumor activity of (-)-hyalodendrin was not only limited to the MCF7 cell lines, but also prominent on cancer cells with invasive phenotypes including colorectal cancer cells resistant to chemotherapy. Further investigations showed that treatment of MCF7-Sh-WISP2 cells with (-)-hyalodendrin induced changes in the phosphorylation status of p53 and altered expression of HSP60, HSP70 and PRAS40 proteins. Altogether, our study reveals that this uninvestigated marine fungal crude extract possesses a strong therapeutic potential against tumor cells with aggressive phenotypes and confirms that members of the epidithiodioxopiperazines are interesting fungal toxins with anticancer activities.


Asunto(s)
Antineoplásicos/farmacología , Ascomicetos/química , Supervivencia Celular/efectos de los fármacos , Hongos/química , Micotoxinas/farmacología , Piperazinas/farmacología , Proteínas Adaptadoras Transductoras de Señales/metabolismo , Animales , Productos Biológicos/farmacología , Línea Celular , Humanos , Células MCF-7 , Ratones , Neoplasias/tratamiento farmacológico , Transducción de Señal/efectos de los fármacos , Reductasa de Tiorredoxina-Disulfuro , Tiorredoxinas , Células Tumorales Cultivadas , Proteína p53 Supresora de Tumor/metabolismo
9.
Viruses ; 11(12)2019 11 27.
Artículo en Inglés | MEDLINE | ID: mdl-31783609

RESUMEN

Autophagy is an essential catabolic process that degrades cytoplasmic components within the lysosome, therefore ensuring cell survival and homeostasis. A growing number of viruses, including members of the Herpesviridae family, have been shown to manipulate autophagy to facilitate their persistence or optimize their replication. Previous works showed that the Epstein-Barr virus (EBV), a human transforming gammaherpesvirus, hijacked autophagy during the lytic phase of its cycle, possibly to favor the formation of viral particles. However, the viral proteins that are responsible for an EBV-mediated subversion of the autophagy pathways remain to be characterized. Here we provide the first evidence that the BALF0/1 open reading frame encodes for two conserved proteins of the Bcl-2 family, BALF0 and BALF1, that are expressed during the early phase of the lytic cycle and can modulate autophagy. A putative LC3-interacting region (LIR) has been identified that is required both for BALF1 colocalization with autophagosomes and for its ability to stimulate autophagy.


Asunto(s)
Autofagia , Infecciones por Virus de Epstein-Barr/virología , Herpesvirus Humano 4/fisiología , Interacciones Huésped-Patógeno , Proteínas Virales/metabolismo , Autofagosomas/metabolismo , Línea Celular Tumoral , Herpesvirus Humano 4/genética , Humanos , Sistemas de Lectura Abierta/genética , Filogenia , Proteínas Virales/genética
10.
Antiviral Res ; 172: 104615, 2019 12.
Artículo en Inglés | MEDLINE | ID: mdl-31580916

RESUMEN

Epstein-Barr virus (EBV) is a widely distributed gamma-herpesvirus that has been associated with various cancers mainly from lymphocytic and epithelial origin. Although EBV-mediated oncogenesis has been associated with viral oncogenes expressed during latency, a growing set of evidence suggested that antiviral treatments directed against EBV lytic phase may contribute to prevent some forms of cancers, including EBV-positive Post-Transplant Lymphoproliferative Diseases. It is shown here that dipyridamole (DIP), a safe drug with favorable and broad pharmacological properties, inhibits EBV reactivation from B-cell lines. DIP repressed immediate early and early genes expression mostly through its ability to inhibit nucleoside uptake. Considering its wide clinical use, DIP repurposing could shortly be evaluated, alone or in combination with other antivirals, to treat EBV-related diseases where lytic replication plays a deleterious role.


Asunto(s)
Dipiridamol/farmacología , Herpesvirus Humano 4/efectos de los fármacos , Activación Viral/efectos de los fármacos , Antivirales/farmacología , Linfocitos B/metabolismo , Linfocitos B/virología , Línea Celular , ADN Viral/efectos de los fármacos , Reposicionamiento de Medicamentos , Infecciones por Virus de Epstein-Barr/tratamiento farmacológico , Expresión Génica/efectos de los fármacos , Herpesvirus Humano 4/genética , Herpesvirus Humano 4/metabolismo , Humanos , Nucleósidos/metabolismo , Latencia del Virus/efectos de los fármacos , Replicación Viral/efectos de los fármacos
11.
Protein Expr Purif ; 162: 44-50, 2019 10.
Artículo en Inglés | MEDLINE | ID: mdl-31145974

RESUMEN

BALF0/1 is a putative Epstein-Barr virus (EBV) protein that has been described as a modulator of apoptosis. So far, the lack of specific immunological reagents impaired the detection of native BALF0/1 in EBV-infected cells. This study describes the expression and purification of a truncated form of BALF0/1 (tBALF0) using a heterologous bacterial expression system. tBALF0 was further used as an antigen in an indirect Enzyme-linked Immunosorbent Assay (ELISA) that unraveled the presence of low titer IgGs to BALF0/1 during primary (10.0%) and past (13.3%) EBV infection. Conversely high-titer IgGs to BALF0/1 were detected in 33.3% of nasopharyngeal carcinoma (NPC) patients suggesting that BALF0/1 and/or humoral response against it may contribute to NPC pathogenesis.


Asunto(s)
Anticuerpos Antivirales/sangre , Infecciones por Virus de Epstein-Barr/sangre , Herpesvirus Humano 4/inmunología , Inmunoglobulina G/sangre , Carcinoma Nasofaríngeo/sangre , Proteínas Virales/inmunología , Anticuerpos Antivirales/inmunología , Ensayo de Inmunoadsorción Enzimática , Infecciones por Virus de Epstein-Barr/virología , Herpesvirus Humano 4/genética , Humanos , Inmunidad Humoral , Inmunoglobulina G/inmunología , Carcinoma Nasofaríngeo/virología , Proteínas Virales/genética
12.
Cancer Drug Resist ; 2(2): 351-355, 2019.
Artículo en Inglés | MEDLINE | ID: mdl-35582718

RESUMEN

Plasticity is an important feature of modern cancer research. However, the level at which we should consider it remains an open question. Such debate is not new in the field of cancer and can be exemplified by the different models explaining carcinogenesis. Those models mostly explain cell transformation through the deregulation of the internal circuitry. In the last years, those models dramatically increased our knowledge and led to a series of short-term successes in terms of therapeutics. However, cancer drug resistance inevitably arises. Recently, studies on the so-called tumor microenvironment enriched the cell-centered perspective but it also enlarged the complexity of cancer etiology in particular for advanced diseases. Here, we suggest that the plastic and multi-sites specific nature of cancer combined with our incapacity to promise cure should push towards a new perspective where early clinical actions, instead of late ones, should be heralded as the priority of cancer research and care.

13.
Chemistry ; 24(62): 16686-16691, 2018 Nov 07.
Artículo en Inglés | MEDLINE | ID: mdl-30168631

RESUMEN

An intramolecular Diels-Alder (IMDA) reaction efficiently accelerated by Schreiner's thiourea is reported, to build a functionalized cytochalasin scaffold (periconiasin series) for biological purposes. DFT calculation highlighted a unique multidentate cooperative hydrogen bonding in this catalysis. The deprotection end game afforded a collection of diverse structures and showed the peculiar reactivity of the Diels-Alder cycloadducts upon functionalization. Biological studies revealed strong cytotoxicity of a few compounds on breast cancer cell lines while actin polymerization is preserved.


Asunto(s)
Antineoplásicos/química , Citocalasinas/química , Citoesqueleto de Actina/efectos de los fármacos , Antineoplásicos/síntesis química , Antineoplásicos/farmacología , Catálisis , Línea Celular Tumoral , Supervivencia Celular/efectos de los fármacos , Cobre/química , Cristalografía por Rayos X , Reacción de Cicloadición , Citocalasinas/síntesis química , Citocalasinas/farmacología , Humanos , Enlace de Hidrógeno , Conformación Molecular , Paladio/química , Estereoisomerismo , Termodinámica , Tiourea/química
14.
J Org Chem ; 83(8): 4871-4881, 2018 04 20.
Artículo en Inglés | MEDLINE | ID: mdl-29596742

RESUMEN

An intramolecular aryne Diels-Alder reaction with a furan moiety was applied to the synthesis of dihydrobenzo[ de]isochromenes as intermediates toward naphthalimides. After oxidation, this method offers an efficient approach for the synthesis of substituted naphthalimides, which showed potent cytotoxic activity against HT-29 human cancer cell line.


Asunto(s)
Antineoplásicos/química , Antineoplásicos/síntesis química , Derivados del Benceno/química , Furanos/química , Naftalimidas/química , Naftalimidas/síntesis química , Reacción de Cicloadición
15.
Clin Cancer Res ; 24(11): 2548-2558, 2018 06 01.
Artículo en Inglés | MEDLINE | ID: mdl-29490990

RESUMEN

Purpose: There is extensive cross-talk between VEGF- and EGFR-pathway signaling in colorectal cancer. However, combinations of VEGF- and EGFR-targeted monoclonal antibodies (mAb) show disappointing activity, in particular for patients with mutant RAS Previous results show that tyrosine kinase inhibitors (TKI) can be active in colorectal cancer models resistant to mAbs. This prompted us to examine whether the activity of bevacizumab can be increased by combination with erlotinib.Experimental Design: The antitumor activity of bevacizumab, erlotinib, and their combination was determined in colorectal cancer models with different RAS status and bevacizumab sensitivity. EGFR/VEGF pathway activation was characterized by immunohistochemistry, Western blot, and ELISA assays. The influence of cetuximab and erlotinib on EGF-mediated migration and the EGFR-EGF ligand feedback loop was established in colorectal cancer cell lines with different RAS status.Results: The addition of erlotinib increased bevacizumab activity in all models independent of RAS status. Bevacizumab exposure was accompanied by marked EGFR activation in tumor cells as well as in tumor-associated endothelial cells (TECs) and resulted in strong accumulation of intracellular EGFR, which could be attenuated by erlotinib. In cellular models, erlotinib was able to attenuate EGF-mediated functions in all cell lines independent of RAS status while cetuximab only showed activity in RAS wild-type cells.Conclusions: These results should provide a molecular framework to better understand the increased activity of the bevacizumab-erlotinib combination, compared with bevacizumab alone, in the GERCOR DREAM phase III clinical trial. Differential activity of mAbs and TKIs targeting the same signaling pathway is likely applicable for other tumor types. Clin Cancer Res; 24(11); 2548-58. ©2018 AACR.


Asunto(s)
Protocolos de Quimioterapia Combinada Antineoplásica/uso terapéutico , Biomarcadores de Tumor , Neoplasias Colorrectales/tratamiento farmacológico , Neoplasias Colorrectales/genética , Proteínas ras/genética , Animales , Protocolos de Quimioterapia Combinada Antineoplásica/efectos adversos , Bevacizumab/administración & dosificación , Línea Celular Tumoral , Neoplasias Colorrectales/patología , Modelos Animales de Enfermedad , Sinergismo Farmacológico , Clorhidrato de Erlotinib/administración & dosificación , Humanos , Ratones , Neovascularización Patológica/genética , Neovascularización Patológica/metabolismo , Pronóstico , Proteínas Proto-Oncogénicas B-raf/genética , Transducción de Señal , Resultado del Tratamiento , Ensayos Antitumor por Modelo de Xenoinjerto , Proteínas ras/metabolismo
16.
J Nat Prod ; 79(12): 2991-2996, 2016 Dec 23.
Artículo en Inglés | MEDLINE | ID: mdl-27966935

RESUMEN

New polyketide-derived oligophenalenone dimers, 9a-epi-bacillisporin E (1) and bacillisporins F-H (2-5), along with the known bacillisporin A (6), were isolated from the fungus Talaromyces stipitatus. Their structures and absolute configurations were determined on the basis of spectroscopic analyses, electronic circular dichroism, and GIAO NMR shift calculation followed by DP4 analysis. The antimicrobial activity of these compounds was evaluated against a panel of human pathogenic bacteria. Among them, bacillisporin H (5) exhibited antimicrobial activity together with modest cytotoxicity against HeLa cells.


Asunto(s)
Antiinfecciosos/aislamiento & purificación , Antiinfecciosos/farmacología , Fenalenos/aislamiento & purificación , Fenalenos/farmacología , Talaromyces/química , Antiinfecciosos/química , Bacterias/efectos de los fármacos , Enterococcus faecalis/efectos de los fármacos , Escherichia coli/efectos de los fármacos , Células HeLa , Humanos , Pruebas de Sensibilidad Microbiana , Estructura Molecular , Resonancia Magnética Nuclear Biomolecular , Fenalenos/química , Microbiología del Suelo , Staphylococcus aureus/efectos de los fármacos
17.
Curr Pharm Des ; 22(44): 6625-6644, 2016.
Artículo en Inglés | MEDLINE | ID: mdl-27587198

RESUMEN

Despite the efficacy of most cancer therapies, drug resistance remains a major problem in the clinic. The eradication of the entire tumor and the cure of the patient by chemotherapy alone are rare, in particular for advanced disease. From an evolutionary perspective, the selective pressure exerted by chemotherapy leads to the emergence of resistant clones where resistance can be associated with many different functional mechanisms at the single cell level or can involve changes in the tumor micro-environment. In the last decade, tumor genomics has contributed to the improvement of our understanding of tumorigenesis and has led to the identification of numerous cellular targets for the development of novel therapies. However, since tumors are by nature extremely heterogeneous, the drug efficacy and economical sustainability of this approach is now debatable. Importantly, tumor cell heterogeneity depends not only on genetic modifications but also on non-genetic processes involving either stochastic events or epigenetic modifications making genetic biomarkers of uncertain utility. In this review, we wish to highlight how evolutionary biology can impact our understanding of carcinogenesis and resistance to therapies. We will discuss new approaches based on applied ecology and evolution dynamics that can be used to convert the cancer into a chronic disease where the drugs would control tumor growth. Finally, we will discuss the way metabolic dysfunction or phenotypic changes can help developing new delivery systems or phenotypetargeted drugs and how exploring new sources of active compounds can conduct to the development of drugs with original mechanisms of action.


Asunto(s)
Antineoplásicos/uso terapéutico , Evolución Biológica , Sistemas de Liberación de Medicamentos , Genotipo , Neoplasias/tratamiento farmacológico , Fenotipo , Resistencia a Antineoplásicos , Humanos , Neoplasias/genética , Neoplasias/patología , Microambiente Tumoral
18.
Oncotarget ; 7(18): 25885-901, 2016 May 03.
Artículo en Inglés | MEDLINE | ID: mdl-27029031

RESUMEN

Trabectedin (Yondelis®, ecteinascidin-743, ET-743) is a marine-derived natural product approved for treatment of advanced soft tissue sarcoma and relapsed platinum-sensitive ovarian cancer. Lurbinectedin is a novel anticancer agent structurally related to trabectedin. Both ecteinascidins generate DNA double-strand breaks that are processed through homologous recombination repair (HRR), thereby rendering HRR-deficient cells particularly sensitive. We here characterize the DNA damage response (DDR) to trabectedin and lurbinectedin in HeLa cells. Our results show that both compounds activate the ATM/Chk2 (ataxia-telangiectasia mutated/checkpoint kinase 2) and ATR/Chk1 (ATM and RAD3-related/checkpoint kinase 1) pathways. Interestingly, pharmacological inhibition of Chk1/2, ATR or ATM is not accompanied by any significant improvement of the cytotoxic activity of the ecteinascidins while dual inhibition of ATM and ATR strongly potentiates it. Accordingly, concomitant inhibition of both ATR and ATM is an absolute requirement to efficiently block the formation of γ-H2AX, MDC1, BRCA1 and Rad51 foci following exposure to the ecteinascidins. These results are not restricted to HeLa cells, but are shared by cisplatin-sensitive and -resistant ovarian carcinoma cells. Together, our data identify ATR and ATM as central coordinators of the DDR to ecteinascidins and provide a mechanistic rationale for combining these compounds with ATR and ATM inhibitors.


Asunto(s)
Protocolos de Quimioterapia Combinada Antineoplásica/farmacología , Proteínas de la Ataxia Telangiectasia Mutada/antagonistas & inhibidores , Carbolinas/farmacología , Dioxoles/farmacología , Compuestos Heterocíclicos de 4 o más Anillos/farmacología , Tetrahidroisoquinolinas/farmacología , Antineoplásicos Alquilantes/farmacología , Daño del ADN/efectos de los fármacos , Células HeLa , Humanos , Reparación del ADN por Recombinación/efectos de los fármacos , Trabectedina
19.
Org Biomol Chem ; 14(9): 2691-7, 2016 Mar 07.
Artículo en Inglés | MEDLINE | ID: mdl-26837531

RESUMEN

Two novel oxaphenalenone dimers, talaroketals A () and B (), were isolated from the soil fungus Talaromyces stipitatus. Their structures and absolute configurations were determined on the basis of spectroscopic analyses, X-ray diffraction experiments and electronic circular dichroism. Compound () features a rare benzannulated 5,6-spiroketal ring system within the dimeric bis(oxaphenalenone) skeleton while the parent compound () harbors a fused bicyclic furano-pyran moiety. These two compounds may biogenetically result from the reaction of duclauxin with a dihydrofuran derivative of botryodiplodin. Additionally, talaroketals A () and B () display modest antimicrobial activity against Staphylococcus aureus.


Asunto(s)
Compuestos Heterocíclicos de 4 o más Anillos/aislamiento & purificación , Compuestos de Espiro/química , Talaromyces/química , Compuestos Heterocíclicos de 4 o más Anillos/química , Modelos Moleculares , Conformación Molecular
20.
Phytochemistry ; 119: 70-5, 2015 Nov.
Artículo en Inglés | MEDLINE | ID: mdl-26386982

RESUMEN

Chemical investigation of the fungus Talaromyces stipitatus ATCC 10500, whose genome has been sequenced, led to the isolation of four undescribed talaroenamines B-E along with the known talaroenamine A. Their structures were elucidated on the basis of spectroscopic studies including mass spectrometry, extensive 2D NMR and electronic circular dichroism (ECD). Interestingly, talaroenamine A had previously been isolated from the strain of T. stipitatus Δtrop C, a strain knocked out for the gene encoding a non-heme Fe(II)-dependent dioxygenase catalyzing the oxidative ring expansion leading to the tropolone, but never from a wild-type strain. All talaroenamines were evaluated for their antiplasmodial activity and Talaroenamine D exhibited the best inhibition against the chloroquine-resistant Plasmodium falciparum (FcB1 strain) without noticeable toxicity on HeLa and preadipose cell lines. In the course of the chemical investigation of T. stipitatus, an undescribed polyester was also isolated and its absolute configuration was determined by hydrolysis and transesterification followed by gas chromatography on chiral column.


Asunto(s)
Antimaláricos/aislamiento & purificación , Antimaláricos/farmacología , Derivados del Benceno/aislamiento & purificación , Cloroquina/farmacología , Plasmodium falciparum/efectos de los fármacos , Policétidos/aislamiento & purificación , Talaromyces/química , Antimaláricos/química , Derivados del Benceno/química , Dicroismo Circular , Dioxigenasas/metabolismo , Resistencia a Medicamentos , Células HeLa , Humanos , Estructura Molecular , Resonancia Magnética Nuclear Biomolecular , Poliésteres/química , Poliésteres/aislamiento & purificación , Policétidos/química
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA
...